Immunocytochemical analysis of the cervical pap smear

Research output: Contribution to journalArticle

Abstract

Although immunostained cervical Pap smears are not yet FDA approved for clinical use, it is very likely that they will become widely employed in the near future to identify neoplastic squamous and iendocervical glandular cells when screening liquid-based cytological preparations (i.e., SurePath™ or ThinPrep™). The current problem with cytology complemented by high-risk human papillomavirus (HPV) testing is poor specificity. HPV testing provides superior sensitivity, but many women are infected with the virus, while very few have had persistent infections leading to carcinoma. Pathologists routinely use antibodies directed against the cyclin-dependent kinase inhibitor p16 (p16INK4a) or a combination of antibodies directed against topoisomerase-2-alpha and minichromosome maintenance protein-2 (as in ProEx™ C) to improve diagnostic precision and accuracy in cervical tissue biopsies. This chapter will describe the immunocytochemical methods used by our group to immunostain cervical Pap smears and provide significantly improved positive predictive value when screening for cervical cancer.

Original languageEnglish (US)
Pages (from-to)203-212
Number of pages10
JournalMethods in Molecular Biology
Volume1249
DOIs
StatePublished - 2015
Externally publishedYes

Fingerprint

Papanicolaou Test
Vaginal Smears
Minichromosome Maintenance Proteins
Cyclin-Dependent Kinase Inhibitor p16
Antibodies
Uterine Cervical Neoplasms
Cell Biology
Viruses
Carcinoma
Biopsy
Infection
Pathologists

Keywords

  • CIN1
  • CIN2+
  • HSIL
  • Immunocytochemistry
  • Ki-67
  • Liquid-based cytology
  • LSIL
  • MCM-2
  • P16
  • Pap smear
  • ProExC
  • Topo-2a

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Medicine(all)

Cite this

Immunocytochemical analysis of the cervical pap smear. / Morgan, Terry; Berlin, Michelle.

In: Methods in Molecular Biology, Vol. 1249, 2015, p. 203-212.

Research output: Contribution to journalArticle

@article{031ff744750d416c887a8697b2e3e5df,
title = "Immunocytochemical analysis of the cervical pap smear",
abstract = "Although immunostained cervical Pap smears are not yet FDA approved for clinical use, it is very likely that they will become widely employed in the near future to identify neoplastic squamous and iendocervical glandular cells when screening liquid-based cytological preparations (i.e., SurePath™ or ThinPrep™). The current problem with cytology complemented by high-risk human papillomavirus (HPV) testing is poor specificity. HPV testing provides superior sensitivity, but many women are infected with the virus, while very few have had persistent infections leading to carcinoma. Pathologists routinely use antibodies directed against the cyclin-dependent kinase inhibitor p16 (p16INK4a) or a combination of antibodies directed against topoisomerase-2-alpha and minichromosome maintenance protein-2 (as in ProEx™ C) to improve diagnostic precision and accuracy in cervical tissue biopsies. This chapter will describe the immunocytochemical methods used by our group to immunostain cervical Pap smears and provide significantly improved positive predictive value when screening for cervical cancer.",
keywords = "CIN1, CIN2+, HSIL, Immunocytochemistry, Ki-67, Liquid-based cytology, LSIL, MCM-2, P16, Pap smear, ProExC, Topo-2a",
author = "Terry Morgan and Michelle Berlin",
year = "2015",
doi = "10.1007/978-1-4939-2013-6_15",
language = "English (US)",
volume = "1249",
pages = "203--212",
journal = "Methods in molecular biology (Clifton, N.J.)",
issn = "1064-3745",
publisher = "Humana Press",

}

TY - JOUR

T1 - Immunocytochemical analysis of the cervical pap smear

AU - Morgan, Terry

AU - Berlin, Michelle

PY - 2015

Y1 - 2015

N2 - Although immunostained cervical Pap smears are not yet FDA approved for clinical use, it is very likely that they will become widely employed in the near future to identify neoplastic squamous and iendocervical glandular cells when screening liquid-based cytological preparations (i.e., SurePath™ or ThinPrep™). The current problem with cytology complemented by high-risk human papillomavirus (HPV) testing is poor specificity. HPV testing provides superior sensitivity, but many women are infected with the virus, while very few have had persistent infections leading to carcinoma. Pathologists routinely use antibodies directed against the cyclin-dependent kinase inhibitor p16 (p16INK4a) or a combination of antibodies directed against topoisomerase-2-alpha and minichromosome maintenance protein-2 (as in ProEx™ C) to improve diagnostic precision and accuracy in cervical tissue biopsies. This chapter will describe the immunocytochemical methods used by our group to immunostain cervical Pap smears and provide significantly improved positive predictive value when screening for cervical cancer.

AB - Although immunostained cervical Pap smears are not yet FDA approved for clinical use, it is very likely that they will become widely employed in the near future to identify neoplastic squamous and iendocervical glandular cells when screening liquid-based cytological preparations (i.e., SurePath™ or ThinPrep™). The current problem with cytology complemented by high-risk human papillomavirus (HPV) testing is poor specificity. HPV testing provides superior sensitivity, but many women are infected with the virus, while very few have had persistent infections leading to carcinoma. Pathologists routinely use antibodies directed against the cyclin-dependent kinase inhibitor p16 (p16INK4a) or a combination of antibodies directed against topoisomerase-2-alpha and minichromosome maintenance protein-2 (as in ProEx™ C) to improve diagnostic precision and accuracy in cervical tissue biopsies. This chapter will describe the immunocytochemical methods used by our group to immunostain cervical Pap smears and provide significantly improved positive predictive value when screening for cervical cancer.

KW - CIN1

KW - CIN2+

KW - HSIL

KW - Immunocytochemistry

KW - Ki-67

KW - Liquid-based cytology

KW - LSIL

KW - MCM-2

KW - P16

KW - Pap smear

KW - ProExC

KW - Topo-2a

UR - http://www.scopus.com/inward/record.url?scp=84921752058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921752058&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-2013-6_15

DO - 10.1007/978-1-4939-2013-6_15

M3 - Article

VL - 1249

SP - 203

EP - 212

JO - Methods in molecular biology (Clifton, N.J.)

JF - Methods in molecular biology (Clifton, N.J.)

SN - 1064-3745

ER -